Galectin Therapeutics (GALT) AI Stock Analysis

• Market Cap: $85.29M
• Dividend Yield: N/A
• Average Volume (3M): 255.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: -1.60%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -0.76
• Shares Outstanding: 63,180,492
• 10 Day Avg. Volume: 238,167
• 30 Day Avg. Volume: 255,175
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -2.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Galectin Therapeutics' low overall score reflects its current financial instability and lack of profitability, typical in early-stage biotech firms. However, promising clinical trial results for belapectin could improve future prospects, indicating potential for long-term growth if further development and partnerships are successful.

Positive Factors

Financial Stability

Galectin's cash runway extends beyond the key data readout, providing financial flexibility before advancing belapectin into Phase 3.

Trial Design

The revised trial design for belapectin's Phase 2b study increases the likelihood of success, as it now has a lower statistical hurdle to meet.

Negative Factors

Investor Sentiment

Investor sentiment on GALT is now rather poor, given this is the second Phase 2b trial to miss its primary endpoint.

Trial Results

The second Phase 2b study of belapectin failed to reach statistical significance on the primary endpoint.

Galectin Therapeutics Business Overview & Revenue Model

Company Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

How the Company Makes Money

Galectin Therapeutics primarily makes money through research and development collaborations, licensing agreements, and milestone payments related to its drug candidates. The company partners with larger pharmaceutical firms to advance the development and commercialization of its therapies, receiving payments for achieving specific research and development milestones. Additionally, Galectin Therapeutics may earn revenue through licensing its proprietary technology and intellectual property to other companies, which can include upfront payments, royalties, and other financial incentives contingent upon the successful commercialization of their drug candidates.

Galectin Therapeutics Financial Statement Overview

Summary

Galectin Therapeutics faces significant financial challenges, characterized by severe operational losses, high financial risk with negative equity, and ongoing cash burn. Reliance on financing is crucial due to unprofitability and insolvency risks.

Income Statement

Galectin Therapeutics shows a challenging financial position in its income statement, with negative revenue growth and poor profitability metrics. The gross profit margin is 66.25% for TTM, but the company remains deeply unprofitable with a net profit margin of -56346.25% due to high operating costs. EBIT and EBITDA margins are also negative, indicating significant operational inefficiencies.

Balance Sheet

The balance sheet reveals high financial risk, with a negative stockholders' equity of -$92.48M in TTM, indicating insolvency. The debt-to-equity ratio is not meaningful as equity is negative. This represents a high-risk financial structure with potential liquidity issues, highlighted by substantial liabilities exceeding assets.

Cash Flow

The cash flow statement shows negative free cash flow and operating cash flow, reflecting ongoing cash burn. Despite this, financing activities have provided some relief by raising funds. The operating cash flow to net income ratio is moderately stable at 0.75 in TTM, but the firm remains reliant on external financing.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
80.00K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
53.00K	-33.00K	-32.00K	-41.00K	-36.00K	-35.00K
	EBIT
-39.57M	-38.07M	-38.35M	-30.18M	-23.44M	-13.44M
	EBITDA
-40.38M	-202.00K	-37.71M	-30.00M	-23.34M	-13.17M
	Net Income Common Stockholders
-45.08M	-41.07M	-39.20M	-30.98M	-23.52M	-13.38M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
120.00K	25.66M	18.59M	39.65M	27.14M	47.48M
	Total Assets
305.00K	28.20M	21.29M	41.83M	29.60M	48.47M
	Total Debt
0.00	71.81M	39.87M	29.06M	44.00K	39.00K
	Net Debt
-120.00K	46.15M	21.28M	-10.59M	-27.10M	-47.44M
	Total Liabilities
6.09M	88.44M	55.20M	40.93M	5.41M	2.87M
	Stockholders Equity
-5.78M	-60.24M	-33.92M	893.00K	29.60M	45.59M
Cash Flow		Free Cash Flow
-33.68M	-32.97M	-31.06M	-24.31M	-20.60M	-10.85M
	Operating Cash Flow
-33.68M	-32.97M	-31.06M	-24.31M	-20.60M	-10.85M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
40.38M	40.03M	10.00M	36.81M	263.00K	50.08M

Galectin Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Negative. The current price of 1.34 is below the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.46, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 44.68 is Neutral, neither overbought nor oversold. The STOCH value of 57.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GALT.

Galectin Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDGL	54 Neutral	$7.00B	―	-80.35%	―	―	-10.89%
ICCC	50 Neutral	$49.40M	―	-8.21%	―	51.63%	62.32%
Sector *	48 Neutral	$6.36B	1.19	-46.31%	2.67%	19.41%	1.23%
ENTA	46 Neutral	$100.05M	―	-69.10%	―	-9.55%	24.57%
VKTX	42 Neutral	$2.50B	―	-17.90%	―	―	-10.27%
GALT	33 Underperform	$85.29M	―	48.74%	―	―	-1.60%

Galectin Therapeutics Corporate Events

Galectin Therapeutics Updates Investors on Clinical Trials

On March 5, 2025, Galectin Therapeutics announced the availability of its updated corporate presentation on its website, intended for use in investor and analyst meetings. The presentation highlights the company’s focus on advancing its clinical trials for Belapectin, which has shown promising results in reducing new varices in MASH cirrhosis patients and in cancer treatment when combined with checkpoint inhibitors. The company is also exploring potential partnerships and funding opportunities to support its ongoing research and development efforts.

Galectin Therapeutics Unveils Promising NAVIGATE Trial Results

On January 23, 2025, Galectin Therapeutics presented significant findings from their NAVIGATE trial during their Annual Meeting of Stockholders. The trial, which concluded successfully in 2024, showed that their drug candidate, belapectin, demonstrated a favorable clinical effect in patients with MASH cirrhosis and portal hypertension. The results included a notable reduction in the incidence of new varices and positive outcomes in non-invasive biomarkers of fibrosis. These findings underscore the company’s commitment to addressing unmet medical needs and position Galectin as a potential leader in this area of treatment. The company plans to further engage with the FDA and potential partners to advance the development of belapectin.